What I really liked about Hany's presentation at JP Morgan:
- market potential presently 2.5bn$ growing very dynamically, of which about 900 mUS$ are accessible with present system and the entire market with the nextgen
- positive cashflow expected with the intro of nextgen end of '13
- GenMark is looking at the global business, which I read as planning to go international
- he said 'unfortunately' he could only talk about Q3 results which to me indicates a great deal of confidence re. full year results
Cheers, all longs!!
PS.: The flu outbreak on the east coast should translate into windfall sales gains in Q1/'13
GNMK reminds me of the yesteryear of Illumina (ILMN). Roche had once made an offer for ILMN but decided to pull out. GNMK may be worth the look. Roche can plant the seeds in GNMK and watch them grow as an independent company.
Interesting you say that. Roche 'planted' Hany Massarany, former Roche Head of Tissue Diagnostics and President of Ventana Medical Systems. And Chairman Chris Gleeson was instrumental in the sale of Ventana to Roche, serving as President and CEO at the time...